These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21149917)

  • 1. Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals.
    Zhu L; Butterton J; Persson A; Stonier M; Comisar W; Panebianco D; Breidinger S; Zhang J; Bertz R
    Antivir Ther; 2010; 15(8):1107-14. PubMed ID: 21149917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients.
    Jansen A; Colbers EP; van der Ven AJ; Richter C; Rockstroh JK; Wasmuth JC; van Luin M; Burger DM
    HIV Med; 2013 Aug; 14(7):449-52. PubMed ID: 23506243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors.
    Calcagno A; Tettoni MC; Simiele M; Trentini L; Montrucchio C; D'Avolio A; Di Perri G; Bonora S
    J Antimicrob Chemother; 2013 Feb; 68(2):482-4. PubMed ID: 23085776
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
    Martin DE; Galbraith H; Schettler J; Ellis C; Doto J
    Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
    Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
    Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.
    Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Conti F; Clementi E
    Ther Drug Monit; 2010 Dec; 32(6):782-6. PubMed ID: 20926993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.
    Iwamoto M; Wenning LA; Mistry GC; Petry AS; Liou SY; Ghosh K; Breidinger S; Azrolan N; Gutierrez MJ; Bridson WE; Stone JA; Gottesdiener KM; Wagner JA
    Clin Infect Dis; 2008 Jul; 47(1):137-40. PubMed ID: 18513146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults.
    Carey D; Pett SL; Bloch M; Wand H; MacRae K; Beileiter K; Ray JE; Boyd MA; Emery S; Cooper DA
    J Acquir Immune Defic Syndr; 2012 Jun; 60(2):143-9. PubMed ID: 22421745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
    Moltó J; Deig E; Valle M; Maria Llibre J; Miranda C; Cedeño S; Valero S; Negredo E; Clotet B
    Ther Drug Monit; 2010 Feb; 32(1):93-6. PubMed ID: 20040897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
    Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ
    J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
    Macassa E; Delaugerre C; Teglas JP; Jullien V; Tréluyer JM; Veber F; Rouzioux C; Blanche S
    Pediatr Infect Dis J; 2006 Sep; 25(9):809-14. PubMed ID: 16940839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-HIV agents. Atazanavir and raltegravir--an interesting combination.
    TreatmentUpdate; 2009; 21(3):3-4. PubMed ID: 19623725
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.
    Burger DM; Agarwala S; Child M; Been-Tiktak A; Wang Y; Bertz R
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3336-42. PubMed ID: 17005814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients.
    Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Fucile S; Clementi E
    Fundam Clin Pharmacol; 2013 Apr; 27(2):216-22. PubMed ID: 22044510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
    Cordery DV; Hesse K; Amin J; Cooper DA
    Antivir Ther; 2010; 15(7):1035-8. PubMed ID: 21041919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.
    Acosta EP; Kendall MA; Gerber JG; Alston-Smith B; Koletar SL; Zolopa AR; Agarwala S; Child M; Bertz R; Hosey L; Haas DW
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3104-10. PubMed ID: 17576825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
    HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
    McRae M; Clay PG; Anderson PL; Glaros AG
    Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers.
    Estévez JA; Moltó J; Tuneu L; Cedeño S; Antonijoan RM; Mangues MA; Clotet B; Domingo P; Puntes M; Barbanoj MJ; Valle M
    J Antimicrob Chemother; 2012 Aug; 67(8):2013-9. PubMed ID: 22566588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Human immunodeficiency virus and Chagas disease coinfection treated successfully with benznidazole and a raltegravir-based antiretroviral regimen: a case report].
    Rodríguez-Guardado A; Tuset M; Asensi V; Miró JM
    Med Clin (Barc); 2011 Sep; 137(6):278-9. PubMed ID: 20980024
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.